One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Luis Alfonso Rojas, Zachary M. Sethna, Kevin C. Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander Chu and 41 more
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA–lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8 + T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Rojas, L. A., Sethna, Z. M., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J. J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., … Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150. https://doi.org/10.1038/s41586-023-06063-y
Rojas, Luis Alfonso, et al. "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer." Nature, vol. 618, no. 7963, 2023, pp. 144–150, https://doi.org/10.1038/s41586-023-06063-y.
Rojas, Luis Alfonso, Zachary M. Sethna, Kevin C. Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, et al. "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer." Nature 618, no. 7963 (2023): 144–150. https://doi.org/10.1038/s41586-023-06063-y.
Rojas L. A., Sethna Z. M., Soares K. C. [и др.] Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer // Nature. — 2023. — Vol. 618, № 7963. — P. 144–150. — URL: https://doi.org/10.1038/s41586-023-06063-y
@article{rojas2023personalized,
title = {{Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer}},
author = {Luis Alfonso Rojas and Zachary M. Sethna and Kevin C. Soares and Cristina Olcese and Nan Pang and Erin Patterson and Jayon Lihm and Nicholas Ceglia and Pablo Guasp and Alexander Chu and Rebecca Yu and Adrienne Kaya Chandra and Theresa Waters and Jennifer Jin Ruan and Masataka Amisaki and Abderezak Zebboudj and Zagaa Odgerel and George Payne and Evelyna Derhovanessian and Felicitas Müller and Ina Park Rhee and Mahesh Yadav and Anton Dobrin and Michel Sadelain and Marta Łuksza and Noah A. Cohen and Laura H. Tang and Olca Baştürk and Mithat Gönen and Seth S. Katz and Richard Kinh Gian and Andrew S. Epstein and Parisa Momtaz and Wungki Park and Ryan Sugarman and Anna M. Varghese and Elizabeth S. Won and Avni Mukund Desai and Alice Chia-Chi Wei and Michael Ian D'Angelica and T. Peter Kingham and Ira Mellman and Taha Merghoub and Jedd D. Wolchok and Uğur Şahin and Özlem Türeci and Benjamin D. Greenbaum and William R. Jarnagin and Jeffrey A. Drebin and Eileen Mary O'Reilly and Vinod P. Balachandran},
journal = {Nature},
year = {2023},
volume = {618},
number = {7963},
pages = {144--150},
doi = {10.1038/s41586-023-06063-y},
url = {https://doi.org/10.1038/s41586-023-06063-y}
}TY - JOUR AU - Rojas, Luis Alfonso AU - Sethna, Zachary M. AU - Soares, Kevin C. AU - Olcese, Cristina AU - Pang, Nan AU - Patterson, Erin AU - Lihm, Jayon AU - Ceglia, Nicholas AU - Guasp, Pablo AU - Chu, Alexander AU - Yu, Rebecca AU - Chandra, Adrienne Kaya AU - Waters, Theresa AU - Ruan, Jennifer Jin AU - Amisaki, Masataka AU - Zebboudj, Abderezak AU - Odgerel, Zagaa AU - Payne, George AU - Derhovanessian, Evelyna AU - Müller, Felicitas AU - Rhee, Ina Park AU - Yadav, Mahesh AU - Dobrin, Anton AU - Sadelain, Michel AU - Łuksza, Marta AU - Cohen, Noah A. AU - Tang, Laura H. AU - Baştürk, Olca AU - Gönen, Mithat AU - Katz, Seth S. AU - Gian, Richard Kinh AU - Epstein, Andrew S. AU - Momtaz, Parisa AU - Park, Wungki AU - Sugarman, Ryan AU - Varghese, Anna M. AU - Won, Elizabeth S. AU - Desai, Avni Mukund AU - Wei, Alice Chia-Chi AU - D'Angelica, Michael Ian AU - Kingham, T. Peter AU - Mellman, Ira AU - Merghoub, Taha AU - Wolchok, Jedd D. AU - Şahin, Uğur AU - Türeci, Özlem AU - Greenbaum, Benjamin D. AU - Jarnagin, William R. AU - Drebin, Jeffrey A. AU - O'Reilly, Eileen Mary AU - Balachandran, Vinod P. TI - Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer JO - Nature VL - 618 IS - 7963 SP - 144 EP - 150 PY - 2023 DA - 2023/05/10 DO - 10.1038/s41586-023-06063-y UR - https://doi.org/10.1038/s41586-023-06063-y ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.